Evidence map›Paper›PMID 41666186›Full record

ArticlePloS one2026

AI-based prediction of recurrence after carbon ion radiotherapy for early stage non-small cell lung cancer.

Yuhei Miyasaka, Hanae Yoshida, Naoko Okano, Hirofumi Shimada, Nobuteru Kubo, Hidemasa Kawamura, Tatsuya Ohno

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuhei MiyasakaGunma University Heavy Ion Medical Center, Maebashi, Japan.ORCID https://orcid.org/0000-0001-5137-1862
Hanae YoshidaGunma University Advanced Particle Beam Medical Science Joint Research Course (Hitachi, Ltd.), Maebashi, Japan.
Naoko OkanoGunma University Heavy Ion Medical Center, Maebashi, Japan.ORCID https://orcid.org/0000-0001-7669-6110
Hirofumi ShimadaGunma University Heavy Ion Medical Center, Maebashi, Japan.
Nobuteru KuboGunma University Heavy Ion Medical Center, Maebashi, Japan.
Hidemasa KawamuraGunma University Heavy Ion Medical Center, Maebashi, Japan.ORCID https://orcid.org/0000-0003-4899-1715
Tatsuya OhnoGunma University Heavy Ion Medical Center, Maebashi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a leading cause of cancer-related deaths. Carbon ion radiotherapy (CIRT) is a treatment modality for patients with inoperable conditions or who decline surgery, but there is room for research to identify patients at high risk of recurrence. The use of artificial intelligence (AI)-based predictive models in healthcare is growing, yet their application in predicting outcomes after CIRT in NSCLC remains unexplored. This study developed an AI prediction model using clinical and imaging data to identify patients at high risk of recurrence after CIRT for early stage NSCLC. Patients with untreated early stage peripheral NSCLC undergoing CIRT between June 2010 and December 2020 were included. Simulated computed tomography (CT) images and clinical data were used to develop a model to predict recurrence within 2 years of CIRT. The model was tested using 5-fold cross-validation and evaluated using receiver operating characteristic (ROC) analysis. The study involved 124 patients. Two-year overall survival, local control, and progression-free survival rates stood at 90.8%, 91.0%, and 69.4%, respectively. The three-axis plane method for CT image input was more predictive than the three-transverse plane or 3D methods. Our AI-based model using CT images and clinical data predicted recurrence within 2 years of CIRT with a median area under the ROC curve of 0.762. Gradient-weighted class activation mapping enhanced model interpretability. The multimodal AI-based model identifies early stage NSCLC patients at high recurrence risk after CIRT although external validation is required for its generalizability and robustness.

Indexed as

Artificial IntelligenceCarcinoma, Non-Small-Cell LungHeavy Ion RadiotherapyLung NeoplasmsNeoplasm Recurrence, LocalAgedFemaleHumansMaleMiddle AgedNeoplasm StagingROC CurveTomography, X-Ray Computed

Identifiers

PMID41666186
PMCPMC12890150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.